Results for eritropoesi translation from Maltese to English

pazjenti li bħalissa mhux ikkurati b’sustanza li tistimula l-eritropoesi (esa):
patients not currently treated with an erythropoiesis stimulating agent (esa):

doża eċċessiva tista ’ tirriżulta f’ manifestazzjonijiet ta ’ effett farmakodinamiku esaġerat, eż. eritropoesi eċċessiva.
overdose can result in manifestations of an exaggerated pharmacodynamic effect, e. g. excessive erythropoiesis.

fi studji kliniċi kkontrollati, l- użu ta ’ neorecormon u sustanzi oħra li jistimolaw l- eritropoesi wrew:
caution should be exercised when prescribing to pregnant women.

doża eċċessiva tista’ tirriżulta f’manifestazzjonijiet ta’ effett farmakodinamiku esaġerat, e.ż. eritropoesi eċċessiva.
overdose can result in manifestations of an exaggerated pharmacodynamic effect, e.g. excessive erythropoiesis.

mircera tistimula l- eritropoesi b’ interazzjoni mar- riċettur ta ’ eritropoetin fuq ċelluli proġenituri fil - mudullun.
mircera stimulates erythropoiesis by interaction with the erythropoietin receptor on progenitor cells in the bone marrow.

mircera jistimula l-eritropoesi permezz ta’ interazzjoni mar-riċettur ta’ eritropoetin fuq ċelluli proġenituri fil-mudullun.
mircera stimulates erythropoiesis by interaction with the erythropoietin receptor on progenitor cells in the bone marrow.

biex tkun żgurata eritropoesi effettiva, l-istat tal-ħadid għandu jkun evalwat fil-pazjenti kollha, qabel u waqt il-kura.
to ensure effective erythropoiesis, iron status has to be evaluated for all patients prior to and during treatment.

139 ta ’ avvenimenti kardjovaskulari serji meta sustanzi li jistimolaw l- eritropoesi (esas) ingħataw biex tintlaħaq emoglobina ta ’ aktar minn 12 g/ dl (7. 5 mmol/ l).
in clinical trials, an increased risk of death and serious cardiovascular events was observed when erythropoiesis stimulating agents (esas) were administered to target a haemoglobin of greater than 12 g/ dl (7.5 mmol/ l).